TABLE. Characteristics of a random sample of patients aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus infection* (N = 1,634), stratified by age and site — Respiratory Syncytial Virus–Associated Hospitalization Surveillance Network, 12 states,† October 2022–April 2023.
| Characteristic | Age group, yrs |
|||||||
|---|---|---|---|---|---|---|---|---|
| Overall |
60–69 |
70–79 |
≥80 |
|||||
| No. | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) | No. | Weighted % (95% CI) | |
|
Total, row %
|
1,634
|
100
|
523
|
32
|
554
|
34
|
557
|
34
|
|
Sex
| ||||||||
| Female |
975 |
60.5 (57.0–63.8) |
311 |
60.7 (54.8–66.4) |
317 |
57.5 (51.7–63.1) |
347 |
62.8 (56.7–68.7) |
| Male |
659 |
39.5 (36.2–43.0) |
212 |
39.3 (33.6–45.2) |
237 |
42.5 (36.9–48.3) |
210 |
37.2 (31.3–43.3) |
|
Race and ethnicity
§
| ||||||||
| AI/AN |
7 |
0.3 (0.1–0.7) |
3 |
0.5 (0.1–1.5) |
4 |
0.5 (0.1–1.5) |
0 |
— |
| A/PI, NH |
95 |
7.1 (5.2–9.5) |
31 |
7.3 (3.6–12.8) |
23 |
3.9 (2.3–6.2) |
41 |
9.8 (6.1–14.6) |
| Black or African American, NH |
213 |
13.0 (11.0–15.2) |
111 |
22.4 (18.0–27.4) |
69 |
13.0 (9.6–17.0) |
33 |
5.7 (3.5–8.7) |
| White, NH |
1,181 |
70.2 (67.0–73.3) |
333 |
60.6 (54.6–66.4) |
404 |
70.2 (64.7–75.4) |
444 |
77.6 (72.1–82.4) |
| Hispanic or Latino |
92 |
6.7 (5.0–8.7) |
33 |
7.2 (4.4–11.0) |
33 |
9.1 (5.5–13.9) |
26 |
4.2 (2.4–6.7) |
| All other races¶ |
5 |
0.4 (0.1–1.3) |
1 |
0.1 (0.0–0.9) |
2 |
0.3 (0.0–1.2) |
2 |
0.7 (0.0–3.3) |
| Unknown |
41 |
2.3 (1.6–3.3 |
11 |
1.9 (0.8–3.6) |
19 |
3.0 (1.7–4.9) |
11 |
2.0 (0.9–3.9) |
|
LTCF residence** |
290 |
17.2 (14.9–19.8) |
36 |
5.8 (3.8–8.5) |
79 |
16.1 (12.0–20.9) |
175 |
26.9 (22.2–32.0) |
|
Viral codetection
††
| ||||||||
| SARS-CoV-2 |
39 |
2.4 (1.5–3.6) |
11 |
1.6 (0.7–3.1) |
19 |
3.4 (1.7–5.9) |
9 |
2.2 (0.8–4.9) |
| Influenza |
23 |
2.2 (1.2–3.8) |
7 |
1.9 (0.4–5.0) |
9 |
2.3 (0.6–5.7) |
7 |
2.4 (0.8–5.5) |
|
Hospitalization outcome§§
| ||||||||
| Hospital stay, days, median (IQR) |
4.1 (2.2–7.6) |
— |
4.0 (2.0–7.4) |
— |
4.1 (2.3–7.7) |
— |
4.2 (2.2–7.7) |
— |
| BiPAP/CPAP |
339 |
19.8 (17.3–22.6) |
116 |
23.3 (18.3–28.9) |
131 |
22.6 (18.1–27.6) |
92 |
14.8 (11.2–19.2) |
| High-flow nasal cannula |
80 |
4.3 (3.2–5.7) |
22 |
3.9 (2.1–6.7) |
31 |
5.4 (3.3–8.2) |
27 |
3.7 (2.2–5.8) |
| ≥1 severe outcome¶¶ |
332 |
18.5 (15.9–21.2) |
112 |
20.5 (16.3–25.3) |
124 |
22.3 (17.2–28.1) |
96 |
13.7 (10.2–17.8) |
| ICU admission |
297 |
17.0 (14.5–19.7) |
111 |
20.5 (16.2–25.2) |
110 |
20.6 (15.5–26.4) |
76 |
11.3 (8.0–15.4) |
| Invasive mechanical ventilation |
94 |
4.8 (3.5–6.3) |
42 |
6.4 (4.4–9.0) |
33 |
4.9 (2.9–7.7) |
19 |
3.5 (1.4–6.9) |
| In-hospital death |
98 |
4.7 (3.6–6.1) |
22 |
3.0 (1.7–4.8) |
39 |
5.8 (3.7–8.5) |
37 |
5.2 (3.2–7.9) |
|
Underlying medical condition
| ||||||||
| ≥1 underlying medical condition*** |
1,584 |
95.5 (93.2–97.2) |
501 |
96.3 (94.0–97.9) |
540 |
97.2 (95.1–98.6) |
543 |
93.5 (87.3–97.2) |
| Chronic lung disease |
813 |
49.2 (45.7–52.7) |
290 |
54.4 (48.2–60.4) |
292 |
53.9 (48.0–59.7) |
231 |
41.2 (35.3–47.3) |
| COPD |
552 |
33.7 (30.5–37.0) |
197 |
38.9 (33.1–44.8) |
189 |
34.4 (28.9–40.4) |
166 |
29.1 (24.0–34.6) |
| Asthma |
332 |
19.1 (16.6–21.8) |
134 |
25.4 (20.4–31.0) |
108 |
16.5 (12.9–20.7) |
90 |
16.4 (12.3–21.2) |
| Other††† |
72 |
5.4 (3.8–7.3) |
17 |
3.0 (1.6–5.1) |
34 |
8.4 (5.0–13.1) |
21 |
4.6 (2.4–8.0) |
| Cardiovascular disease |
1,108 |
67.1 (63.7–70.5) |
304 |
55.0 (48.8–61.0) |
371 |
67.5 (61.8–72.8) |
433 |
76.3 (70.0–81.8) |
| CHF§§§ |
545 |
33.2 (30.0–36.5) |
165 |
31.5 (26.1–37.2) |
165 |
29.8 (24.4–35.7) |
215 |
37.4 (31.7–43.4) |
| CAD¶¶¶ |
435 |
26.4 (23.5–29.5) |
109 |
20.9 (16.3–26.3) |
151 |
28.8 (23.7–34.4) |
175 |
28.6 (23.6–34.1) |
| CVA**** |
253 |
13.7 (11.7–15.9) |
55 |
9.6 (6.9–13.0) |
90 |
14.0 (10.7–17.8) |
108 |
16.7 (12.8–21.1) |
| Immunocompromising condition |
292 |
18.6 (16.0–21.4) |
101 |
19.0 (14.5–24.1) |
121 |
22.8 (18.0–28.1) |
70 |
14.8 (10.8–19.6) |
| Diabetes mellitus |
553 |
32.6 (29.5–35.8) |
200 |
38.0 (32.4–43.9) |
195 |
32.7 (27.6–38.1) |
158 |
28.4 (23.1–34.2) |
| Neurologic condition |
439 |
27.3 (24.3–30.5) |
96 |
17.3 (13.4–21.7) |
135 |
25.2 (20.3–30.6) |
208 |
36.8 (31.0–42.9) |
| Dementia†††† |
183 |
12.4 (10.1–15.0) |
7 |
1.0 (0.4–2.4) |
40 |
8.5 (5.5–12.5) |
136 |
24.5 (19.4–30.1) |
| Other |
256 |
14.9 (12.6–17.4) |
89 |
16.2 (12.5–20.6) |
95 |
16.7 (12.6–21.4) |
72 |
12.3 (8.8–16.6) |
| Kidney disorder |
477 |
29.3 (26.3–32.5) |
134 |
24.7 (19.7–30.1) |
156 |
30.0 (24.8–35.5) |
187 |
32.3 (26.9–38.0) |
| Obesity | 572 | 37.8 (34.3–41.4) | 230 | 46.4 (40.3–52.5) | 213 | 42.4 (36.5–48.6) | 129 | 27.1 (21.3–33.6) |
Abbreviations: AI/AN = American Indian or Alaska Native; A/PI = Asian or other Pacific Islander; BiPAP/CPAP = bilevel positive airway pressure/continuous positive airway pressure; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CVA = cerebrovascular accident; ICU = intensive care unit; LTCF = long-term care facility; NH = non-Hispanic.
* Data are from a weighted sample of hospitalized adults with completed medical record abstractions. Sample sizes presented are unweighted with weighted percentages.
† Includes persons admitted to a hospital with an admission date during October 1, 2022–April 30, 2023. Selected counties in California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Oregon, Tennessee, and Utah.
§ If ethnicity was unknown, NH ethnicity was assumed.
¶ Includes NH persons reported as other or multiple races.
** LTCF residents include hospitalized adults who were identified as residents of a nursing home or skilled nursing facility, rehabilitation facility, assisted living or residential care, long-term acute care hospital, group or retirement home, or other LTCF upon hospital admission. A free-text field for other types of residences was examined; patients with an LTCF-type residence were also categorized as LTCF residents.
†† Results reported among adults who received testing (as opposed to all hospitalized adults). Because of testing practices, denominators differed among the viral respiratory pathogens based on type of test results available: SARS-CoV-2 = 95% (1,553) and influenza (influenza A, influenza B, and flu [not subtyped]) = 97% (1,587). Among 375 (24.2%) patients who received testing for other viruses, 15 additional viruses were detected: nine rhinoviruses, four seasonal coronaviruses, and two parainfluenza viruses.
§§ Hospitalization outcomes are not mutually exclusive categories, and patients can be included in more than one category.
¶¶ Severe outcome is defined as requiring ICU admission or mechanical ventilation or experiencing in-hospital death.
*** Defined as one or more of the following: chronic lung disease, including asthma; chronic metabolic disease including diabetes mellitus; blood disorder or hemoglobinopathy; cardiovascular disease; neurologic disorder; immunocompromising condition; renal disease; gastrointestinal or liver disease; rheumatologic, autoimmune, or inflammatory condition; obesity; feeding tube dependency; and wheelchair dependency.
††† Other chronic lung diseases include interstitial lung disease, pulmonary fibrosis, restrictive lung disease, sarcoidosis, asbestosis, and chronic respiratory failure including oxygen dependence.
§§§ CHF includes cardiomyopathy, heart failure with preserved ejection fraction, and heart failure with reduced ejection fraction.
¶¶¶ CAD includes history of coronary artery bypass graft and myocardial infarction.
**** CVA includes history of stroke or transient ischemic attack.
†††† Dementia includes Alzheimer disease and other types of dementia.